KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Other Accumulated Expenses (2016 - 2025)

Pfizer (PFE) has disclosed Other Accumulated Expenses for 16 consecutive years, with $18.6 billion as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses fell 5.44% to $18.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18.6 billion through Dec 2025, down 5.44% year-over-year, with the annual reading at $18.6 billion for FY2025, 5.44% down from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $18.6 billion at Pfizer, down from $19.5 billion in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $24.9 billion in Q4 2021, with the low at $12.8 billion in Q2 2021.
  • Average Other Accumulated Expenses over 5 years is $19.6 billion, with a median of $19.7 billion recorded in 2022.
  • The sharpest move saw Other Accumulated Expenses skyrocketed 115.72% in 2021, then plummeted 32.49% in 2023.
  • Over 5 years, Other Accumulated Expenses stood at $24.9 billion in 2021, then decreased by 9.51% to $22.6 billion in 2022, then dropped by 9.0% to $20.5 billion in 2023, then fell by 3.98% to $19.7 billion in 2024, then decreased by 5.44% to $18.6 billion in 2025.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods came in at $18.6 billion, $19.5 billion, and $18.6 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.